Dose-Finding and Efficacy Confirmation Trial of the Superselective Intra-arterial Infusion of Cisplatin and Concomitant Radiation Therapy for Locally Advanced Maxillary Sinus Cancer (JCOG1212): Results of the Efficacy Confirmation Phase in Patients with T4aN0M0

Purpose: Locally advanced maxillary sinus cancers require radical surgery as a standard treatment, but this often results in signi fi cant dis fi gurement and impairment of function. JCOG1212 seeks to evaluate the safety and ef fi cacy of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy (RADPLAT) for T4aN0M0 and T4bN0M0 maxillary sinus squamous cell carcinomas. We herein report the results of the ef fi cacy con fi rmation phase in the T4a cohort. Methods and Materials: Patients received 100 mg/m(2) cisplatin intra-arterially weekly for 7 weeks with concomitant radiation therapy (total 70 Gy) as determined by the results of the preceding dose - fi nding phase. The trial aimed to evaluate the primary endpoint of 3 -year overall survival (OS), comparing RADPLAT with the historical control for 3 -year OS in surgery (80%). Results: From April 2014 to August 2018, 65 patients were registered in the T4a cohort from 18 institutions, consisting of 54 men and 11 women with a median age of 64 years (range, 40-78 years) and Eastern Cooperative Oncology Group performance status 0/1 (58/7). After excluding 1 ineligible patient, 64 patients were included in the primary analysis of ef fi cacy and safety. The median follow-up was 4.5 years in all eligible patients, and the primary endpoint for 3 -year OS was 82.8% (90% CI, 73.4%-89.2%). With regard to acute adverse events, mucositis (grade >= 3), neutropenia (grade >= 3), increased creatinine (grade >= 2), hearing impairment (grade >= 2), and stroke (grade >= 2) were observed in 20.3%, 14.1%, 3.1%, 3.1%, and 1.6% of patients, respectively. One treatment -related death due to a thromboembolic event was reported. Conclusions: We demonstrated that RADPLAT showed favorable results for patients with T4aN0M0 maxillary sinus squamous cell carcinomas compared with the historical control for 3 -year OS in surgery, which was from an earlier period, and showed some specific toxicities. Therefore, RADPLAT, as well as surgery, can be regarded as a possible treatment option for these patients. (c) 2023 Elsevier Inc. All rights reserved.